What is the ideal dilution for N‑acetylcysteine (NAC) infusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

N-Acetylcysteine Infusion Dilution

N-acetylcysteine (NAC) must be diluted to 5% dextrose in water (D5W), 0.45% sodium chloride, or 0.9% sodium chloride prior to intravenous administration, as the concentrated solution is hyperosmolar (2600 mOsmol/L) and cannot be given undiluted. 1

Standard Dilution Protocol

The FDA-approved preparation requires dilution based on the three-bag dosing regimen:

Loading Dose (First Bag)

  • 150 mg/kg in 200 mL of diluent administered over 60 minutes
  • For patients <40 kg: adjust total volume to 3 mL/kg to prevent fluid overload

Second Dose

  • 50 mg/kg in 500 mL of diluent administered over 4 hours

Third Dose

  • 100 mg/kg in 1000 mL of diluent administered over 16 hours

1

Alternative Simplified Dilution

A simplified single-bag preparation of 30 g NAC in 1 L of D5W has been successfully used off-label, with a 150 mg/kg loading dose over 1 hour followed by 14 mg/kg/hour for 20 hours. This approach reduces medication errors while maintaining equivalent drug exposure. 2

Research demonstrates that NAC 60 mg/mL diluted in 0.9% sodium chloride, 0.45% sodium chloride, or D5W remains chemically and physically stable for at least 72 hours when stored in PVC bags at room temperature. 3

Critical Dilution Considerations

The hyperosmolar nature of undiluted NAC (2600 mOsmol/L) makes dilution mandatory to prevent vascular irritation and adverse reactions. 1 The osmolarity of the final solution varies based on diluent choice and NAC concentration, but all recommended dilutions bring osmolarity to physiologically acceptable ranges.

Oral Administration Alternative

When IV access is unavailable or contraindicated, NAC can be given orally at 140 mg/kg loading dose followed by 70 mg/kg every 4 hours for 17 doses, diluted to a 5% solution (typically in juice or soft drinks to mask the sulfur taste). 4

Common Pitfalls

  • Never administer undiluted NAC intravenously - the hyperosmolar solution causes severe adverse reactions
  • Rapid infusion of the loading dose increases anaphylactoid reaction risk; maintain the 60-minute infusion time
  • For patients requiring fluid restriction or weighing <40 kg, reduce total diluent volume proportionally (3 mL/kg minimum)
  • The three-bag FDA regimen has a 33% medication error rate due to complexity; simplified regimens may improve safety 2, 5

The choice between D5W, 0.45% sodium chloride, or 0.9% sodium chloride as diluent depends on institutional preference and patient-specific factors (e.g., hyperglycemia, electrolyte abnormalities), as all three maintain NAC stability and efficacy. 1, 3

Related Questions

Should N‑acetylcysteine (NAC) be administered concurrently with the maintenance IV fluids, or given as a separate IV infusion alone?
What is the appropriate dosing regimen for intravenous N‑acetylcysteine?
Can potassium chloride be administered intravenously together with an N‑acetylcysteine (NAC) infusion in 5% dextrose?
What is the recommended N‑acetylcysteine dosing regimen for acetaminophen (paracetamol) overdose in adults and children?
What is the recommended dilution for nebulised N‑acetylcysteine?
What is the importance of high‑flow nasal cannula oxygen therapy in the hospital setting?
What is the appropriate management for fulminant amoebic colitis?
Should I obtain a chest CT scan for a patient presenting with melanopsia?
If my patient is having hemoptysis, should I obtain a chest computed tomography (CT) scan?
What is the appropriate management for an infusion reaction to amivantamab?
What is the appropriate assessment and plan for a 79‑year‑old woman with a history of coronary artery disease status post triple coronary artery bypass graft (left internal mammary artery to left anterior descending artery and saphenous vein grafts to obtuse marginal branches), hypertension, hyperlipidemia, chronic obstructive pulmonary disease, obstructive sleep apnea, and heart failure with reduced ejection fraction (35‑40 %), who presented with severe hypertension and chest pain, was diagnosed with a non‑ST‑elevation myocardial infarction, underwent percutaneous coronary intervention with a drug‑eluting stent to the obtuse marginal branch, and now has bradycardia, hypotension, mildly elevated creatinine, and is taking aspirin, ticagrelor, bempedoic‑acid/ezetimibe, losartan/hydrochlorothiazide, isosorbide mononitrate, and sertraline?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.